DE69126301T2 - Hiv-induzierte synzytien blockierender anti-cd-4-antikörper - Google Patents

Hiv-induzierte synzytien blockierender anti-cd-4-antikörper

Info

Publication number
DE69126301T2
DE69126301T2 DE69126301T DE69126301T DE69126301T2 DE 69126301 T2 DE69126301 T2 DE 69126301T2 DE 69126301 T DE69126301 T DE 69126301T DE 69126301 T DE69126301 T DE 69126301T DE 69126301 T2 DE69126301 T2 DE 69126301T2
Authority
DE
Germany
Prior art keywords
antibody
seq
cells
hiv
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69126301T
Other languages
German (de)
English (en)
Other versions
DE69126301D1 (de
Inventor
Linda C. West Newton Ma 02165 Burkly
Patricia L. Quincy Ma 02169 Chisholm
Joseph J. Winchester Ma 01890 Rosa
Margaret D. Winchester Ma 01890 Rosa
David W. Wellesley Ma 02181 Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of DE69126301D1 publication Critical patent/DE69126301D1/de
Publication of DE69126301T2 publication Critical patent/DE69126301T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69126301T 1990-11-27 1991-11-27 Hiv-induzierte synzytien blockierender anti-cd-4-antikörper Expired - Lifetime DE69126301T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61854290A 1990-11-27 1990-11-27
PCT/US1991/008843 WO1992009305A1 (en) 1990-11-27 1991-11-27 Anti cd-4 antibodies blocking hiv-induced syncytia

Publications (2)

Publication Number Publication Date
DE69126301D1 DE69126301D1 (de) 1997-07-03
DE69126301T2 true DE69126301T2 (de) 1998-01-02

Family

ID=24478147

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69126301T Expired - Lifetime DE69126301T2 (de) 1990-11-27 1991-11-27 Hiv-induzierte synzytien blockierender anti-cd-4-antikörper

Country Status (12)

Country Link
US (1) US5871732A (enExample)
EP (1) EP0512112B1 (enExample)
JP (5) JPH05505112A (enExample)
AT (1) ATE153536T1 (enExample)
AU (1) AU662891B2 (enExample)
CA (1) CA2073031C (enExample)
DE (1) DE69126301T2 (enExample)
DK (1) DK0512112T3 (enExample)
ES (1) ES2101834T3 (enExample)
GR (1) GR3024274T3 (enExample)
OA (1) OA10079A (enExample)
WO (1) WO1992009305A1 (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5651970A (en) * 1993-03-19 1997-07-29 Allen; Allen D. Method for inhibiting disease associated with the human immunodeficiency virus through the use of monoclonal antibodies directed against anti-self cytotoxic T-lymphocytes or their lytics
DE4435950A1 (de) * 1994-10-07 1996-04-11 Hoechst Ag Copolymerisate mit cyclischen oder polycyclischen Monomeren mit einer speziellen Isomerenverteilung und deren Einsatz in Beschichtungsmitteln
US5961976A (en) * 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
AU3044697A (en) * 1997-06-24 1999-01-04 Norman Godin A composition for specific immunoprotection and method for obtaining said comp osition
US6420545B1 (en) * 1999-05-24 2002-07-16 The Trustees Of The University Of Pennsylvania CD4-independent HIV envelope proteins as vaccines and therapeutics
JP2003533968A (ja) * 1999-09-03 2003-11-18 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 免疫グロブリンスーパーファミリーポリヌクレオチド、ポリペプチド、および抗体
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
AU2003299085B2 (en) * 2002-09-27 2008-04-10 Tanox, Inc. Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
WO2007094983A2 (en) * 2006-02-03 2007-08-23 Tanox, Inc. Methods and compositions for the inhibition of hiv infection of t cells
AU2007286451A1 (en) * 2006-08-17 2008-02-21 F. Hoffmann-La Roche Ag A conjugate of an antibody against CCR5 and an antifusogenic peptide
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
CL2008000707A1 (es) 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
EP3067368A1 (en) 2007-04-27 2016-09-14 Genentech, Inc. Potent, stable and non-immunosuppressive anti-cd4 antibodies
AR067584A1 (es) * 2007-07-20 2009-10-14 Hoffmann La Roche Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos
RU2539110C2 (ru) * 2008-03-13 2015-01-10 Биотест Аг Способ лечения аутоиммунного заболевания (варианты)
EP2262838B1 (en) * 2008-03-13 2016-04-13 Biotest AG Agent for treating disease
MX2010010027A (es) * 2008-03-13 2011-05-02 Biotest Ag Agente para tratar enfermedad.
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
RU2531548C2 (ru) * 2008-09-29 2014-10-20 Биотест Аг Композиция для лечения заболевания
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
CN102321653B (zh) * 2011-07-18 2013-11-20 清华大学 人鼠嵌合型cd4质粒及其多抗在抑制hiv感染中的应用
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
JP6408487B2 (ja) 2012-12-18 2018-10-24 ザ ロックフェラー ユニバーシティ Ｈｉｖの防止および療法のためのグリカン修飾された抗ｃｄ４抗体
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US11180555B2 (en) 2014-09-16 2021-11-23 Ubi Us Holdings, Llc. Antibodies directed against CD4 for the treatment and functional cure of HIV
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
AU2016273213B2 (en) 2015-06-01 2019-03-14 Medigene Immunotherapies Gmbh T cell receptor library
WO2016193300A1 (en) 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh Method for generating antibodies against t cell receptor
US9925258B2 (en) 2015-10-02 2018-03-27 International Aids Vaccine Initiative Replication-competent VSV-HIV Env vaccines
TWI752930B (zh) 2015-12-23 2022-01-21 德商梅迪基因免疫治療公司 抗原特異性ｔｃｒ的新生成
AU2017312887A1 (en) 2016-08-13 2019-03-07 United BioPharma, Inc. Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients
CN112175087B (zh) * 2019-07-02 2022-05-13 深圳市迈加瑞生物技术有限公司 一种抗CD4和TGFβ的双特异性抗体、其药物组合及其用途
TWI845745B (zh) * 2019-08-19 2024-06-21 洛克菲勒大學 具改良藥物動力學之經酸鹼度依賴性抗原結合活性工程化之抗人類免疫缺乏病毒抗體
WO2021062546A1 (en) * 2019-10-01 2021-04-08 Taimed Biologics Inc. Use of ibalizumab for the treatment of hiv-2 infection
MX2023004299A (es) 2020-10-13 2023-07-07 Univ Pennsylvania Direccionamiento de células t cd4+ in vivo para terapeuticos de arnm.
CN112500491B (zh) 2020-12-18 2022-04-08 深圳市迈加瑞生物技术有限公司 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途
EP4381081A1 (en) 2021-08-04 2024-06-12 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
JP2025510948A (ja) * 2022-03-31 2025-04-15 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ４特異的抗体構築物及び組成物ならびにその使用
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
US20260027145A1 (en) 2022-07-27 2026-01-29 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
EP4590688A1 (en) 2022-09-21 2025-07-30 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024112867A1 (en) 2022-11-23 2024-05-30 University Of Georgia Research Foundation, Inc. Compositions and methods of use thereof for increasing immune responses
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
CN117659192A (zh) * 2023-10-19 2024-03-08 深圳市福元生物科技有限公司 Cd4纳米抗体的制备及其应用
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652447A (en) * 1979-04-26 1987-03-24 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human helper T cells
US4381295A (en) * 1979-04-26 1983-04-26 Ortho Pharmaceutical Corporation Monoclonal antibody to human helper T cells and methods of preparing same
US4515895A (en) * 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing monoclonal antibody to human helper T cells
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4653020A (en) * 1983-10-17 1987-03-24 International Business Machines Corporation Display of multiple data windows in a multi-tasking system
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
EP0347435A4 (en) * 1987-09-04 1991-11-21 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing soluble t4 proteins
US4908203A (en) * 1987-09-09 1990-03-13 Johnson & Johnson Method for inducing HIV neutralizing antibodies using an internal image idiotope
WO1989009782A1 (en) * 1987-10-14 1989-10-19 United States Of America, Represented By The Secre New anti-receptor peptides and therapeutic agents
WO1990004978A1 (en) * 1988-11-01 1990-05-17 Becton Dickinson And Company Method of directing immune response to a viral binding site
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies

Also Published As

Publication number Publication date
EP0512112B1 (en) 1997-05-28
HK1007686A1 (en) 1999-04-23
JP2002356499A (ja) 2002-12-13
WO1992009305A1 (en) 1992-06-11
JPH05505112A (ja) 1993-08-05
OA10079A (en) 1996-12-18
JP2005041859A (ja) 2005-02-17
CA2073031A1 (en) 1992-05-28
EP0512112A1 (en) 1992-11-11
ES2101834T3 (es) 1997-07-16
US5871732A (en) 1999-02-16
CA2073031C (en) 2002-10-01
GR3024274T3 (en) 1997-10-31
JP2007151556A (ja) 2007-06-21
AU662891B2 (en) 1995-09-21
DE69126301D1 (de) 1997-07-03
ATE153536T1 (de) 1997-06-15
JP2007175055A (ja) 2007-07-12
AU9154391A (en) 1992-06-25
DK0512112T3 (da) 1997-09-29
JP4642035B2 (ja) 2011-03-02

Similar Documents

Publication Publication Date Title
EP0512112B1 (en) Anti cd-4 antibodies blocking hiv-induced syncytia
DE69434499T2 (de) Monoklonale Antikörper und Fv gegen das CD2 Antigen
DE69433422T2 (de) Monoklonaler anti-hiv antikörper
DE69431797T2 (de) Verfahren und Stoffe zur Modulation der immunsuppressiven Aktivität und Toxitätvon monoklonalen Antikörpern
DE69100768T2 (de) CD25-bindende Moleküle.
DE69231135T2 (de) CD2 bindender Bereich für das Lymphocyten-Funktion assoziierte Antigen-3
JP3121823B2 (ja) 抗体におけるまたは抗体に関する改良
US5817767A (en) Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same
DE69308573T2 (de) Bispezifische immunoadhesine
DE69129743T2 (de) Humanisierte chimäre anti-"icam-1" antikörper, herstellungsverfahren und verwendung
DE69226877T2 (de) Behandlung der hiv-assoziierten immun-thrombopenie purpura
DE69031591T2 (de) Cd4-spezifischer rekombinanter antikörper
DE69131564T2 (de) Multimere Formen des menschlichen Rhinovirus-Rezeptorproteins
DE69535133T2 (de) Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4
DE68923675T2 (de) Interzellulare Adhäsions-Moleküle und deren Bindungsliganden.
CN101720232A (zh) 具有修饰的效应器功能的fc受体结合型多肽
EP0528951A1 (en) Humanized cdr-grafted anti-icam-1 antibodies, methods of preparation and usage thereof
DE69233480T2 (de) CD4-gamma2- und CD4-IgG2-Chimären
DE69736474T2 (de) Antikörper gegen einen komplex aus cd4 und einer chemokinrezeptordomäne, sowie deren verwendung gegen hiv infektionen
DE69029294T2 (de) Nichtmenschliche primaten CD4-Polypeptide und menschliche glykosilierbare CD4-Moleküle
DE68907735T2 (de) Genfragmente, die die variable Region eines Anti-HIV-Antikörpers codieren, von diesen exprimierte chimäre Anti-HIV-Antikörper und Verfahren zu deren Herstellung.
DE69232295T2 (de) Verfahren zur Verbesserung der Toleranz für Allotransplantaten und Xenotransplantaten durch Verabreichung eines LFA-3- oder CD2-Bindungsproteins
DE69028713T3 (de) Schimäre immunoglobuline für cd4-rezeptoren
HK1007686B (en) Anti cd-4 antibodies blocking hiv-induced syncytia
JP2011024593A (ja) Ａｉｄｓ、ａｒｃおよびｈｉｖ感染の予防および治療に有用な抗ｃｄ４抗体ホモログ

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BIOGEN IDEC MA INC., CAMBRIDGE, MASS., US